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Abstract
Background: Patients with acute myocardial infarction are at high risk for acute kidney injury. Novel biomarkers
that can predict acute kidney injury in AMI may allow timely interventions. C-terminal fragment of agrin (CAF), a
proteoglycan of the glomerular and tubular basement membrane, have been recently associated with rapid renal
function deterioration and proximal tubular dysfunction. It is unknown whether elevated CAF levels may serve as a
novel AKI biomarker in patients presenting with AMI.
Methods: In 436 persons enrolled in a multicenter prospective observational cohort study of patients with acute
myocardial infarction, we measured plasma and urine levels of several kidney injury biomarkers including CAF,
neutrophil gelatinase-associated lipocalin (NGAL), interleukin-18 (IL-18) and cystatin-C.The relationship between
biomarker levels at baseline and the development of AKI and long-term mortality were analyzed after adjustment
for demographic and clinical variables.
Results: AKI incidence was up to 15% during hospitalization. The predictive accuracy for AKI of urinary CAF was
similar to NGAL and superior to other tested kidney injury biomarkers. In a multivariate model that included all
possible confounding variables only urinary CAF continued to be an independent marker for AKI (OR 1.35 95%CI 1.
05 -1.74). During the 2 years follow-up, only plasma CAF levels remained a significant independent predictor of
mortality (OR 2.5 95%CI 1.02-6.2; P = 0.04).
Conclusions: Elevated CAF levels are associated with AKI in patients with acute myocardial infarction. Our study
provides preliminary evidence that CAF levels may predict AKI and mortality after AMI in low risk patients with
relative preserved kidney function at baseline.
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Background
Acute kidney injury (AKI) is a common complication
after acute myocardial infarction (AMI). Early diagnosis
and subsequent management of AKI after AMI remains
challenging, since the AKI etiology is multifactorial. In
AMI, impaired renal function may result from deterior-
ating heart function, nephrotoxic contrast agents or due
to underlying kidney disease [1–3]. In addition, AKI
classification is primarily based on serum creatinine
changes mostly occurring days after the initial insult.
The need for better biomarkers of AKI prediction has
been acknowledged as a crucial barrier to improvement
of the outcomes after AMI. The ideal, “troponin-like”
renal injury biomarker should be able to help stratify
patients at risk for AKI before any critical intervention
or contrast media admission. Several urinary and plasma
proteins have been proposed as potential biomarkers for
predicting AKI in AMI.These include renal function
markers such as cystatin C (Cyst-C) and specific renal
injury markers, such as interleukin 18 (IL-18), neutrophil
gelatinase-associated lipocalin (NGAL) and kidney injury
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molecule-1 (KIM-1) [4–7]. All these biomarkers however,
are still not widely applied and have been associated with
various clinical limitations particularly in low risk
patients [8, 9].
Agrin which is a large proteoglycan serves as a major
heparan sulfate proteoglycan for the glomerular and the
tubular basement membrane and is highly expressed in
the kidney. Agrin serves also as a ubiquitous component
of the extracellular matrix [10]. Cleavage of agrin by the
serine protease neurotrypsin at the beta site produces
the 22 kDa C-terminal fragment (CAF22) [11]. Elevated
serum CAF22 (sCAF) has recently emerged as a promis-
ing biomarker for kidney function and is highly associ-
ated with other renal markers in septic patients, renal
transplant recipients and patients with chronic kidney
disease. [11–13]. In previous studies we were able to
show that baseline urinary CAF22 levels were associated
with subsequent eGFR loss and proteinuria progression
in diabetic nephropathy [14]. In animal models we were
able to show that CAF22 was cleared from circulation
primary by glomerular filtration and that filtered CAF22
was reabsorbed by the proximal tubule [15]. Based on
our findings we postulated that CAF22 may represent a
novel renal injury biomarker which may reflect both
renal function and indirectly proximal tubular integrity.
Therefore, we performed a post-hoc analysis of a large
prospective multicenter study with AMI patients in
order to explore the association of CAF as early bio-
markers for AKI prediction at hospital admission and to




The study design of this prospective observational
cohort study has been previously published [16]. In short
consecutive patients with acute ST-elevation MI
(STEMI) or non ST-elevation MI (NSTEMI) were
recruited if they fulfilled the following inclusion criteria:
1) age ≥ 18 years; 2) ability to provide written, informed
consent; and 3) acute, spontaneous (type 1) AMI. The
main exclusion criteria were presence of pre-existing
renal disease and AMI-related symptom onset ≥72 h
from hospital admission. Patients referred for urgent
coronary artery bypass grafting and those suffering a
fatal event during the index hospitalization were also
excluded from the study.
Consecutive patients admitted to the Coronary Care
Unit from 3 different Cardiology Departments (Alexan-
droupolis; Kavala; Athens) in Greece were recruited
from July 2010 to May 2014 [16]. In 436 patients,
baseline plasma and urine samples were available for
additional assessment of CAF concentrations and 403
patients had a valid result for all plasma and urine
biomarkers. STEMI patients underwent either primary
percutaneous coronary intervention (PCI), or fibrinolysis
followed by rescue or elective PCI as indicated [17, 18].
NSTEMI patients underwent invasive or primarily
conservative (followed by elective PCI) strategy accord-
ing to current recommendations [18, 19]. Patients were
assessed for presence of AKI at 48 h post admission using
the Acute Kidney Injury Network (AKIN) [20] and the
Acute Dialysis Quality Initiative [Risk, Injury and Failure
(RIFLE)] criteria [21] and also at hospital discharge using
the RIFLE criteria and the Kidney Disease: Improving Glo-
bal Outcomes (KDIGO) criteria [22]. Changes in absolute
or relative changes in creatinine, or eGFR were presumed
to have occurred within hospitalization. In addition, in
each patient a transthoracic echocardiography study was
performed during hospitalization using standard tech-
niques [23]. Death from any or cardiovascular causes,
repeat hospitalization and need for dialysis or other renal
replacement therapy was assessed with telephone contacts
during the 2-years follow up.
Sample collection and measurement
Blood and urine sampling for CAF, FE-Na, NGAL, IL-18
and cyst-C assessment was performed at hospital admis-
sion and before any critical intervention according to
previously established analytical protocols. Peripheral
blood samples for measurement of blood chemistry
(renal function) and full blood count were obtained from
all patients on admission, 48 h after the index event, and
also daily until discharge. Blood samples were drawn
from a peripheral vein of the patients in vacutainer tubes
containing EDTA as an anticoagulant. Samples were im-
mediately centrifuged at 4000 rpm for 10 min at ambient
temperature, and the extracted plasma was stored in ali-
quots and frozen at −70 °C until use. Urine samples
were collected in aliquots from spot urine during admis-
sion and were immediately frozen at -70 °C until use.
[24]. The coefficients of variation for intra- and inter-
assay precision were <8% and <10% respectively, for all
assays. CAF levels were measured using the NTtotalCAF
ELISA kit from Neurotune [14]. The lower detection
limit was 40 pM. Data for plasma were valid when the
coefficient of variation (%CV) was below 20%. Independ-
ent analysis revealed a mixed intra- and inter-assay %CV
below 12.6% for plasma samples.
Study oversight
The study was approved by the institutional Ethics Com-
mittee, and all subjects gave written informed consent at
the time of enrollment. The CAF sample kits measure-
ments were performed blindly by Neurotune AG Schweiz,
which had no role in data analysis.
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Statistical analysis
Data are presented as percentages for categorical data,
as means ± standard deviation (SD) for continuous vari-
ables that were normally distributed and as medians
with interquartile range (IQR) for non-normally distrib-
uted data. Comparisons between categorical variables
were performed by chi- square test or Fisher’s exact test
when required. Differences in continuous variables be-
tween two groups were assessed using the Student’s t-
test or the Mann-Whitney’s U-test as appropriate.
The diagnostic accuracy of the under investigation bio-
markers was determined by calculating the area under
the curve (AUC), sensitivity, specificity, and positive and
negative predictive values using receiver operating char-
acteristic (ROC) curve analysis. The association between
CAF levels and incidence of AKI during hospitalization
was assessed by univariable logistic regression analyses.
For both assessments serum creatinine on admission
were considered as baseline. Independence of the associ-
ation was assessed in multivariable logistic regression
analysis models arbitrarily using variables that could act
as possible cofounders for prognosis (age, diabetes melli-
tus, presence of anemia, glomerular filtration rate on ad-
mission, albuminuria, LV EF, invasive or not treatment
strategy of the index event, presence of any adverse
event during the index hospitalization and infarct size
based on CPK maximum levels). For all (incidence or
prognosis) logistic regression analysis models, odds ra-
tios (OR) with 95% confidence intervals were calculated.
A p value <0.05 was considered to indicate statistical
significance; all tests were two-sided. The IBM SPSS Sta-
tistics 20.0 statistical software package (SPSS Inc., Chi-
cago, Illinois, USA) was used for all calculations with an
exception of AUC comparison and Cochran-Armitage
test for trend for which MedCalc 19.2 Statistical Soft-




Baseline demographic, clinical, angiographic and labora-
tory characteristics of the cohort and in AKI versus non-
AKI patents according to RIFLE-Criteria are listed in
Table 1. The majority of the patients were managed in-
vasively during hospitalization and one fourth of the
population experienced at least one in-hospital adverse
event.
Incidence of AKI
The incidence of AKI in our study population ranged
from 7% to 15% (Additional file 1: Table S1) depending
on timing (at 48 h vs. during hospitalization) and on def-
inition used (AKIN vs. RIFLE vs. KDIGO). The majority
of the patients had stage 1 kidney injury whereas none
of the patients required dialysis during hospitalization.
For further analysis, patients were considered to have
AKI using the KDIGO or RIFLE criteria during
hospitalization.
Relationship between plasma and urine concentrations of
biomarkers with plasma creatinine levels and AKI
CAF concentrations in both mediums were significantly
correlated with creatinine levels on admission (urine;
Spearman’s rho 0.233, P < 0.001, plasma; Spearman’s rho
0.175, P < 0.001). This significant association was also
observed with creatinine levels 48 h post admission
(urine; Spearman’s rho 0.263, P < 0.001, plasma; Spear-
man’s rho 0.226, P < 0.001) and with peak creatinine
levels (urine; Spearman’s rho 0.317, P < 0.001, plasma
Spearman’s rho 0.225, P < 0.001) during hospitalization.
The observed incidence of AKI increased across quar-
tiles of urine CAF (Cochrane-Armitage test for trend
with increasing quartile values; chi-square for trend,
10.99; P < 0.001). The association between increasing
levels of urine CAF and the predicted incidence of AKI
suggested a linear effect (r2 = 0.983). Finally, CAF
concentrations were also significantly associated with
Cyst-C levels both in plasma (Spearman’s rho 0.292, P <
0.001) and in urine (Spearman’s rho 0.267, P < 0.001).
Diagnostic performance
From the under investigation variables only urine
NGAL, urine (u) and plasma (p) CAF were capable of
detecting AKI. The discriminating ability (regarding the
incidence of AKI during hospitalization) of the urine
concentration of the parameters under investigation
ranged from good to moderate whereas from plasma
levels only plasma CAF had a moderate discriminating
ability for AKI occurrence (Table 2). In comparison,
urinary CAF had a similar diagnostic accuracy for AKI
as assessed with ROC analysis compared to urine NGAL
(p = 0.73), and plasma CAF (p = 0.38) (Fig. 1). Indexing
these markers to BMI, BSA, and urine creatinine or
using their urine to plasma ratio did not improve their
diagnostic accuracy (Additional file 1: Table S2).
Diagnostic accuracy
Concerning diagnostic accuracy, ROC analysis identified
a value of 1033 pM as optimal in predicting develop-
ment of AKI. The sensitivity of urinary CAF was 37%
(95%CI 25-51%) and the specificity 85% (95%CI 81-89)
with a negative predictive value of 89% (95%CI 85-92%)
and a positive predictive value of 30% (95%CI 20-42%).
Moreover, the urinary CAF cut-off was associated with a
positive likelihood ratio (+LR) of 2.52 (95% CI 1.7 -3.8)
and a negative ratio (−LR) of 0.7 (95% CI,0.6 -0.9). Ap-
plying Bayes’ theorem, if we consider 15% as the pre-test
probability for developing AKI, the post-test probability
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Table 1 Demographic, clinical and angiographic data at
baseline and in-hospital characteristics of study cohort
Variable Study Cohort (n = 403)
Age, years 62 (13)
Age > 70 years, n(%) 132 (33)
BMI, Kg/m2 28 (4)
BSA, m2 a 1.97 (0.2)
Male/Female, n(%) 314 (78) / 89 (22)
Risk Factors
Hypertension, n(%) 226 (56)
Diabetes mellitus, n(%) 104 (26)
Dyslipidemia, n(%) 161 (40)
Current smokers, n(%) 219 (54)
Co-morbidities
Previous MI, n(%) 65 (16)
Chronic heart failure, n(%) 6 (1.5)
Peripheral arterial disease, n(%) 22 (6)




Valvular disease, n(%) 5 (1)
Previous PCI, n(%) 45(11)
Previous CABG, n(%) 10 (2.5)
Anemia, n(%) 66 (16)
Laboratory Data
Glucose at admission, mg/dl 153 (70)
Hematocrit at admission, % 42 (5)
Hemoglobin at admission, g/dL 14.2 (1.7)
Baseline creatinine, mg/dL 0.98 (0.25)
Creatinine at 48 h, mg/dL 1.03 (0.31)
Peak Creatinine during hospitalization, mg/dL 1.12 (0.47)
Baseline eGFR, mL/min b 94 (35)
eGFR at 48 h, mL/min b 91 (38)
Lowest eGFR during hospitalization, mL/min b 85 (33)
Baseline eGFR classification, n(%)
>90 ml/min 199 (49)
60-90 ml/min 142 (35)
<60 ml/min 62 (16)
Ejection fraction during hospitalization, n(%)
Normal (>55%) 230 (57)
Mildly reduced (45-55%) 106 (26)
Moderately reduced (35-44%) 60 (14.5)
Severely reduced (<35%) 7 (1.5)
Total Cholesterol, mg/dL 204 (49)
LDL Cholesterol, mg/dL 129 (43)
Table 1 Demographic, clinical and angiographic data at
baseline and in-hospital characteristics of study cohort
(Continued)
HDL Cholesterol, mg/dL 44 (18)
Triglycerides, mg/dL 155 (98)
CPK at admission, IU/L 201 (106-566)
CK-MB at admission, IU/L 32 (19-62)
Peak CPK during hospitalization, IU/L 1130 (400-2001)
Peak CK-MB during hospitalization, IU/L 91 (37-179)
Peak CRP during hospitalization, mg/dL 4.3 (1.45-8.90)
Hospitalization Data
Type of Acute Coronary Syndrome
STEMI, n(%) 288 (71)
NSTEMI, n(%) 115 (29)
Site of MI
Inferior, n(%) 129 (32)
Anterior, n(%) 169 (41.5)
Lateral, n(%) 42 (10)
Infero-lateral, n(%) 13 (3.5)
Antero-lateral, n(%) 47(11.5)
Posterior, n(%) 3 (1.5)
Heart rate at admission, bpm 80 (18)
Systolic BP at admission, mmHg 135 (26)
Diastolic BP at admission, mmHg 78 (12)
Low BP (<90 mmHg) at admission, n(%) 20 (5)
Time from symptom onset, hours 6.5 (2-11)
TIMI risk score, n 3 (1-4)
Killip class, n(%)
Class I 368 (91)
Class II 24 (6)
Class III 8 (2)
Class IV 3 (1)
Coronary artery disease, n(%)




Left main stem disease 25 (6)
ACS treatment strategy, n(%)
Invasive during hospitalization 261 (65)
Primarily conservative 142 (35)
IV treatment with, n(%)
Thrombolysis 172 (42)
GP IIb/IIIa inhibitors 50 (12.5)
β-blockers 38 (9.5)
Use of inotropic support 17 (4)
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for developing AKI, when urinary CAF levels are ≥1033
pM, is doubled to 30% (95% CI, 22-40). Similarly, the
post-test probability for developing AKI, when the urin-
ary CAF concentrations are <1033 pM, is only 11% (95%
CI, 9-13). Applying the Bayes theorem in terms of
number needed to diagnose using the cut-off value of
1033 pM, 1 in 3 positive tests are truly predictive of
the disease whilst 1 in 1 negative tests are truly non-
predictive of the disease.
Table 1 Demographic, clinical and angiographic data at
baseline and in-hospital characteristics of study cohort
(Continued)
(catecholamine use or balloon counterpulsation)
Diuretics 27 (6)
Anti-arrhythmics 48 (11.5)
Adverse events, n(%) 96 (23)
Recurrent ischemia 20 (5)
Re-infarction 14 (3.5)
Hemodynamic collapse [9] 16 (4)
Tachyarrhythmia requiring intervention 38 (9.5)
Bradyarrhythmia requiring intervention 13 (3.5)
Acute heart failure during hospitalization 31 (7)
Major bleeding complications [10] 3 (1)
Acute mitral valve regurgitation (severe) 4 (1)
Pericarditis 3 (1)
Hospitalization (days) 5 (4-7)
Prior Medication Use
ACE- inhibitors, n(%) 128 (31)
Angiotensin receptor blockers, n(%) 89 (22)
Diuretics, n(%) 65 (16)
Aldosterone antagonists, n(%) 18 (4)
Nitrates, n(%) 36 (8)
Digitalis, n(%) 11 (2.5)
β- blockers, n(%) 123 (30.5)
Calcium channel blockers, n(%) 43 (10)
Amiodarone, n(%) 15 (3.5)
Statins, n(%) 164 (40)
Fibrates, n(%) 1 (0.2)
Aspirin, n(%) 115 (28)
P2Y12 antiplatelets, n(%) 108 (26)
Anticoagulants, n(%) 9 (2)
Anti-diabetics, n(%) 55 (13)
Metformin, n(%) 35 (8)
Insulin, n(%) 16 (4)
Values are expressed as means (with the corresponding standard deviation) or
medians (with the corresponding interquartitile range) for continuous
variables, and as numbers of patients and percentages for
categorical variables
ACE angiotensin converting enzyme, BMI body mass index, BP blood pressure,
CABG coronary artery bypass graft surgery, CK-MB creatinine kinase myocardial
fraction, CPK creatine phosphokinase, CRP C-reactive protein, eGFR estimated
glomerular filtration rate, GP glycoprotein, HDL high density lipoprotein, IV
intravenous, MI myocardial infarction, NSTEMI non ST elevation myocardial
infarction, LDL low density lipoprotein, CAF C- terminal agrin fragment levels,
Cyst-C cystatin-C, IL-18 interleukin-18, NGAL neutrophil gelatinase-associated
lipocalin, PCI, percutaneous coronary intervention, STEMI ST elevation myocardial
infarction, TIA transient ischemic attack, TIMI Thrombolysis in
myocardial infarction
aCalculated using the Mosteller formula
bCalculated using the Cockcroft-Gault formula
Table 2 Discriminating ability (area under the curve) of the
under investigation variables regarding the incidence of AKI
during hospitalization
AUC 95% CI P value Sens Spec +PV -PV
Urine
IL-18 0.538 0.450-0.626 0.35
NGAL 0.616 0.540-0.692 0.004 75 45 19 91
Cyst-C 0.573 0.489-0.657 0.07
CAF 0.630 0.552-0.708 0.001 37 85 30 89
Plasma
IL-18 0.530 0.440-0.619 0.47
NGAL 0.522 0.438-0.606 0.6
Cyst-C 0.571 0.492-0.650 0.08
CAF 0.587 0.509-0.666 0.03 71 47 19 90
AKI acute kidney injury, AUC area under the curve, CAF C-terminal agrin
fragment, CI confidence interval, Cyst-C cystatin-C, IL-18 interleukin-18, NGAL
neutrophil gelatinase-associated lipocalin, n/a non-applicable, Sens sensitivity,
Spec specificity, +PV positive predictive value, −PV negative predictive value
Fig. 1 Comparison of predictive accuracy for AKI of under investigation
markers using ROC analysis in the study cohort. Blue line, urinary CAF;
Green line, plasma CAF; Grey line, NGAL. AKI, acute kidney injury; NGAL,
neutrophil gelatinase-associated lipocalin; plasma CAF, plasma C-terminal
agrin fragment
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Multivariate modeling
Levels of urinary CAF were associated with AKI inci-
dence in a univariate model (OR per 1 SD, 1.45 95%CI
1.15-1.82, P = 0.002). The observed association was
more robust compared to those observed with plasma
CAF levels (OR per 1 SD, 1.41 95%CI 1.11-1.79,
P = 0.005) and urine NGAL levels (OR per 1 SD, 1.15
95%CI 0.93-1.42, P = 0.2).
Levels of urinary CAF continued to be associated with
AKI incidence in a multivariate model (Table 3) that in-
cluded multiple variables (age, diabetes mellitus, pres-
ence of anemia, glomerular filtration rate on admission,
albuminuria, LV EF, invasive or not treatment strategy of
the index event, presence of any adverse event during
the index hospitalization and infarct size based on CPK
maximum levels) with an OR 1.35 95%CI 1.05 -1.74. Of
interest, neither urine NGAL (P = 0.62), nor plasma CAF
(P = 0.24) concentrations were independent predictors of
AKI in multivariable models. The addition of urinary
CAF levels in predictive models including each one of
the 3 comparator biomarkers resulted in increased dis-
criminating ability. Furthermore, the addition of urinary
CAF levels to a predictive model including all 3 bio-
markers (urine NGAL and plasma CAF) showed a better
predictive performance. However, the additive value of urin-
ary CAF levels was marginally non-significant. (Additional
file 1: Table S3)
Long-term outcome
During the 2-year follow up, 33 deaths were observed
among the whole study population. Twenty-six deaths
were attributed to cardiovascular causes whereas the rest
7 were attributed to other causes mainly cancer. 57 pa-
tients required at least one repeat hospitalization during
the follow up period, whilst 15 patients developed
deterioration in their kidney function that required an
inpatient intervention or outpatient follow up. Of inter-
est only 2 out of the 15 patients required permanent
renal replacement therapy.
Only plasma CAF levels were associated with death
from any cause (OR 4.1 95%CI 1.7-9.7; P = 0.001)
whereas urinary CAF concentration were not associated
(P = 0.84). Multivariable analysis showed that plasma
CAF levels remained a significant independent predictor
of mortality (OR 2.5 95%CI 1.02-6.2; P = 0.04). Neither
plasma CAF (P = 0.08) nor urinary CAF (P = 0.8) were
predictive of deterioration of kidney function albeit
plasma CAF levels were marginally non-significant.
Discussion
In this study, we analyzed and compared the precision
and discriminative ability of CAF to previous reported
set of biomarkers concerning AKI prediction after AMI.
Our results indicate 1) that urinary CAF has an equiva-
lent ability compared to NGAL for AKI prediction in
low risk patients and 2) in multivariable analysis plasma
CAF levels remained a significant independent predictor
of mortality. Moreover these findings were observed in
patients with relative preserved kidney function at
baseline, and before any AMI related critical interven-
tions.The association between CAF and traditional renal
function and injury parameters was recently demon-
strated by our group in type II diabetics and previously
in septic and transplanted patients. [13, 14, 25] In this
cohort of patients with relative preserved renal function
CAF concentrations in urine and plasma were signifi-
cantly correlated with established renal function parame-
ters such as creatinine and Cyst-C levels on admission.
AKI is a well-recognized complication in patients with
AMI and in our study population AKI occurred in up to
15%. This is in accordance to previous studies reporting a
high incidence of AKI ranging from 10 to 27% based on the
definition applied [26–28]. Findings from the present study
showed that from the under investigation biomarkers only
urine NGAL, urinary CAF and plasma CAF levels were cap-
able of detecting AKI. The urinary CAF concentrations were
characterized by a fair discriminating ability. Urine NGAL
and plasma CAF were also capable of detecting AKI
Table 3 Multivariate analysis
Multivariate analysis
OR 95%CI P value
Age 1.03 0.99-1.07 0.165
Diabetes Mellitus 1.83 0.96-3.51 0.067
CPK peak levels (IU/L) 1.01 0.99-1.02 0.056
Hemoglobin (g/dL) 0.81 0.65-0.99 0.003
GFR baseline (ml/min) 1.01 0.99-1.02 0.194
Albuminuria 0.295
0-30 mg/g n/a
30-300 mg/g 1.43 0.73-2.81 0.302
> 300 mg/g 2.09 0.79-5.46 0.133
LV Ejection fraction 0.002
Normal (>55%) n/a
Mildly reduced (45-55%) 2.01 0.98-4.12 0.057
Moderately reduced (35-44%) 3.64 1.71-9.77 0.001
Severely reduced (<35%) 7.58 1.45-39.29 0.016
Invasive vs conservative treatment 0.88 0.46-1.68 0.691
Presence of adverse event 1.56 0.78-3.12 0.208
Presence of adverse events refer to recurrent ischemia, re-infarction,
hemodynamic collapse, tachyarrhythmia requiring intervention, bradyarrhythmia
requiring intervention, acute heart failure during hospitalization, major bleeding
complications, acute mitral valve regurgitation (severe), pericarditis
The method use was backward deletion method using the Likelihood Ratio
criterion according which all variables were entered in the model and for each
step the worse performing variable (according to the criterion used) was
discarded. Therefore, the significant variables were, except from CAF22,
hemoglobin levels, LV ejection fraction, and marginally diabetes mellitus and
myocardial infract size (using CPK peak levels)
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however with lesser potency. Although the urinary CAF
AUC of 0.630 is suboptimal for short term diagnostic deci-
sions, one should take into account the low risk profile of
our cohort patients. Also in the subgroup of elderly patient
(>70 years old) and those with GFR ≤ 90 ml/min, CAF pro-
vided better prognostic performance with an AUC of 0.7.
Furthermore different definitions of AKI provided a simi-
larly robust predictive ability. Levels of urinary CAF contin-
ued to be associated with AKI incidence in a multivariate
and neither urine NGAL, nor plasma CAF concentrations
were independent predictors of AKI in multivariate models.
Concerning long-term outcome, patients with baseline
elevated levels of plasma CAF were less likely to survive
long-term. Numerous studies and meta-analysis evalu-
ated the diagnostic significance of IL-18, NGAL and
Cyst-C mainly in the context of AKI and long-term mor-
tality after cardiac surgery and in intensive care patients
with multiple comorbidities [29–31]. It is possible that
the insufficient discriminatory ability of other biomarkers
in the present study is attributable to the clinical charac-
teristic of our low risk AMI population.
Although the exact mechanism of CAF production
and trafficking in the kidney is currently under investiga-
tion, previous findings from animal experiments support
the hypothesis that CAF may reflect both structural and
functional alterations [14, 15]. After more than a decade
of research in the field of “novel” biomarkers for AKI we
are still in search for a troponin-like biomarker which is
easily measured, independent of other biological vari-
ables, and that provides both early detection and risk
stratification. A holistic approach, beyond biochemical
biomarkers, that will enhance the clinical value added by
patient history and risk profile is necessary to objectively
individualize care and identify patients for therapeutic
trials. Our previous work on the development of an eas-
ily applicable risk score model for the prediction of
contrast-induced AKI and the current finding arising
from this study, represent a solid basis for future clinical
interventional trials [32].
Our findings have limitation since that in this observa-
tional prospective study most of the patients had stage 1
kidney injury whereas none of the patients developed
AKI requiring dialysis during hospitalization. This post-
hoc analysis lacks information contrast media type and
volume used during the interventions. Strengths include
the more liberal definition of AKI (KDIGO or RIFLE cri-
teria met during hospitalization) allowing us to include
any possible confounding factors for the development
of AKI and the thorough characterization of risk fac-
tors, comorbidities and hemodynamic parameters.
Conclusion
In conclusion, our study provides preliminary evidence
that CAF levels can predict AKI and mortality after AMI
in low risk patients with relative preserved kidney func-
tion at baseline.
Additional file
Additional file 1: Table S1. Acute kidney injury incidence based on
AKIN/RIFLE Criteria at 48 h after admission and based on KDIGO/RIFLE
Criteria during hospitalization. Table S2. Diagnostic performance of
markers after Indexing them to BMI, BSA, and urine creatinine or using
their urine to plasma ratio. Table S3. Performance measures of biomarker
multivariate models predicting AKI. (DOCX 16 kb)
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